Moderna Q1 2023 Earnings Financial Results

Moderna's first quarter 2023 earnings presentation covering financial results, business review, and forward-looking guidance. The presentation discusses anticipated COVID-19 vaccine sales, preparations for RSV and flu vaccine launches in 2024, and clinical trial timelines for respiratory and oncology programs including individualized neoantigen therapy.